Principal Research Associate in Integrative Genomics

Email: dsp35@medschl.cam.ac.uk

Tel: +44 (0)1223 761918

ResearchGate | ORCID | PubMed

Background

Dr Paul graduated with a BSc and MSc in Life Science from the University of Konstanz (Germany) in 2008. With the support of Marie Curie and Wellcome Trust Fellowships, Dr Paul completed a PhD in Molecular Biology and Genetics under the supervision of Prof Panos Deloukas at the Wellcome Sanger Institute in 2012, where he combined experimental and computational approaches to uncover the molecular mechanisms of genetic variants associated with haematological traits. He did postdoctoral studies in epigenomics of immune-related diseases in Prof Stephan Beck’s laboratory at University College London as part of the BLUEPRINT Consortium. In 2015, Dr Paul joined the Cardiovascular Epidemiology Unit as University Lecturer in Integrative Genomics. His current projects are focused on the translation of genomic discoveries in cardiovascular and immune-related diseases into biological and clinical insights.

 

Research Interests

The mission of the Integrative Genomics Team is to identify and characterise causal biological pathways in cardiovascular disease. We integrate computational analyses and cutting-edge experimental strategies to uncover the molecular, cellular and physiological mechanisms underlying genetic associations with cardiovascular disease. Learn more on the Team’s website.

 

Selected Recent Publications

*joint first author, ^#joint last author

Paige E*, Clément M*, Lareyre F, Sweeting M, Raffort J, Grenier C, Finigan A, Harrison J, […], Freitag DF^#, Paul DS^# & Mallat Z^# (2019). Interleukin-6 receptor signalling and abdominal aortic aneurysm growth rates. Circ. Genom. Precis. Med. 12(2), e002413.

Alasoo K, Rodrigues J, Danesh J, Freitag DF, Paul DS^# & Gaffney DJ^# (2019). Genetic effects on promoter usage are highly context-specific and contribute to complex traits. eLife 8, e41673.

Stacey D, Fauman EB, Ziemek D, Sun BB, Harshfield EL, Wood AM, Butterworth AS, Suhre K & Paul DS (2019). ProGeM: a framework for the prioritization of candidate causal genes at molecular quantitative trait loci. Nucleic Acids Res. 47(1), e3.

Sun BB*, Maranville JC*, Peters JE*, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, […], Paul DS, Fox CS, Plenge RM, Danesh J, Runz H^# & Butterworth AS^# (2018). Genomic atlas of the human plasma proteome. Nature 558(7708), 73-9.

Farahi N*, Paige E*, Balla J, Prudence E, Ferreira RC, Southwood M, Appleby SL, Bakke P, […], Danesh J, Paul DS, Freitag DF^# & Chilvers ER^# (2017). Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma. Hum. Mol. Genet. 26(8), 1584-96.

Ecker E, Chen L, Pancaldi V, Bagger FO, Fernández JM, Carrillo de Santa Pau E, Juan D, Mann AL, […], Rico D^#, Valencia A^#, Beck S^#, Soranzo N^# & Paul DS^# (2017). Genome-wide analysis of differential transcriptional and epigenetic variability across human immune cell types. Genome Biol. 18(1), 18.

Chen L*, Ge B*, Casale FP*, Vasquez L*, Kwan T, Garrido-Martín D, Watt S, Yang Y, […], Paul DS, Stunnenberg HG, Stegle O, Downes K, Pastinen T^# & Soranzo N^# (2016). Genetic drivers of epigenetic and transcriptional variation in human immune cells. Cell 167(5), 1398–1414.

Paul DS*, Teschendorff AE*, Dang MA*, Lowe R*, Hawa MI, Ecker S, Beyan H, Cunningham S, […], Rakyan VK^#, Beck S^# & Leslie RD^# (2016). Increased DNA methylation variability in type 1 diabetes across three immune effector cell types. Nature Commun. 7, 13555.